31.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bioqual
Its shares trade under the ticker BIOQ. It has been listed since 14 July 1983. In the fiscal year to 31 May 2026, it reported revenue of $39.9m and a net loss of $4.2m. At that date it held total assets of $68.4m and shareholders' equity of $32.4m.
Bioqual, Inc. engages in the provision and development of medical research and consulting services to commercial clients and government laboratories. The company is headquartered in Rockville, Maryland. The firm supports the National Institutes of Health by providing research services in the research areas of cancer, acquired immune deficiency syndrome (AIDS), hepatitis, influenza, immunology, transgenics, contraception, breeding and development of genetically defined animals, and neurobiology and behavior. The firm's research contracts consist of cancer virus studies, congenic animal development and monoclonal antibody research. The firm's research services include primate biology and medicine, small laboratory animal sciences, infectious disease research, in vitro laboratory services, environmental enrichment and behavior, good laboratory practice (GLP) studies, and partnerships for contracts and grants. The firm holds government contracts, which utilize the non-human primate model to study assorted human diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Jul 1983
- Employees
- 108
- Website
- bioqual.com ↗
Leadership
Pay as last reported
- Mr. Mark LewisChairman of the Board, since 2015
- Dr. Hanne ElyardPresident, Chief Executive Officer
- Mr. Charles KirkChief Financial Officer
- MITCH FRANKLINVice President - Operations
- Mr. Chander SarmaVice President - Facility Operations, Director - Information Technology, since 2015
- Nancy MaddenVice President - Administration Operations, Biosafety Officer, Responsible Official
- Hanne AndersenDirector of Research
- Ms. Amy JohnstonDirector
- Dr. David LandonDirector
- Mr. David NewcomerDirector, since 1989$123,785
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established reputation in the industry for scientific research and experimentation.
- Extensive expertise in conducting pre-clinical research studies.
- Strong network of partnerships with leading pharmaceutical and biotech companies.
Weaknesses
- Relatively small team of expert researchers, which may limit the number of projects the company can undertake simultaneously.
- Limited financial resources, potentially hindering investment in new technologies and equipment.
- Dependence on a few major clients for a significant portion of revenue, posing a risk if any of these clients reduce their contracts.
Opportunities
- Growing demand for pre-clinical research services in the healthcare industry.
- Advancements in technology that can enhance research capabilities and attract more clients.
- Expansion into emerging markets with less competition and potential for strategic partnerships.
Threats
- Intense competition from larger and well-established research organizations.
- Strict regulatory environment and increasing compliance requirements in the industry.
- Economic downturns affecting funding for research and development projects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.